Skip to main content
. 2020 Jan 20;86(5):868–879. doi: 10.1111/bcp.14191

Table 2.

Number (n) of users of the most commonly used drugs classified as P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) substrates (S) or inhibitors (I) in the P‐pg/BCRP polytherapy group

Drug n P‐gp transporter substrate/inhibitor BCRP transporter substrate/inhibitor
Cetirizine 3242 S, I
Progesterone 2985 I
Oestradiol (17‐β) 2813 I
Fluticasone (nasal) 2765 S
Azithromycin 2369 S, I
Fluticasone (inhalation) 1976 S
Budesonide (inhalation) 1955 S
Prednisolone 1893 S
Citalopram 1835 S, I
Diclofenac 1426 S, I
Omeprazole 1202 S, I I
Pantoprazole 1137 S, I S, I
Loratadine 1028 S
Roxithromycin 1020 S, I
Desloratadine (descarboethoxyloratadine) 973 S
Clarithromycin 805 S, I
Levocetirizine ((R)‐cetirizine) 787 S
Sertraline 757 I
Propranol 749 I
Sulfasalazine 741 S S, I
Montelukast 725 I
Quetiapine 717 I
Ranitidine 717 S
Lansoprazole 715 S, I I
Metformin 710 S S
Erythromycin 586 S, I S
Prednisone 537 S
Ciprofloxacin 469 S S
Methylprednisolone 458 S I
Etoricoxib 449 I